Limited Competition: Biospecimen Banks to support NCI National Clinical Trials Network (NCTN)(U24 Clinical Trial Not Allowed)

0
216

Funding Opportunity ID: 321879
Opportunity Number: RFA-CA-20-002
Opportunity Title: Limited Competition: Biospecimen Banks to support NCI National Clinical Trials Network (NCTN)(U24 Clinical Trial Not Allowed)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Cooperative Agreement
Category of Funding Activity: Education
Health
Category Explanation:
CFDA Number(s): 93.394
Eligible Applicants: Public and State controlled institutions of higher education
Additional Information on Eligibility: Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed. See FOA for full eligibility details.
Agency Code: HHS-NIH11
Agency Name: Department of Health and Human Services
National Institutes of Health
Posted Date: Oct 24, 2019
Close Date: Dec 17, 2019
Last Updated Date: Oct 24, 2019
Award Ceiling: $3,000,000
Award Floor: $0
Estimated Total Program Funding: $17,230,000
Expected Number of Awards: 5
Description: This Funding Opportunity Announcement (FOA) solicits renewal applications for Biobanks that will support the following NCI clinical trial programs: The NCI National Clinical Trials Network (NCTN; https://research.usc.edu/nci-national-clinical-trials-network-nctn-program/), and NCI Community Oncology Research Program (NCORP). The NCTN Biospecimen Bank (also referred to as NCTN Biobanks) will be responsible for collecting, processing, storing, and distributing well-annotated human specimens from patients with cancer who are participating in NCI-funded NCTN Phase II-III and other clinical treatment trials (CTEP/Division of Cancer Treatment and Diagnosis; DCTD). The main goal is to support NCTN with the state-of the-art banking infrastructure and operations including maintenance of up-to-date specimen inventory. The NCTN Biobanks will distribute to qualified investigators the biospecimens linked to high-quality clinical data (including treatment and outcome information) that are critical for developing and validating biomarkers for cancer diagnosis, prognosis and prediction of responses to therapy. The NCTN Biobanks will work in collaboration with NCTN Groups and Group Statistical and Data Management Centers as well as affiliated institutions to ensure effective operation. Each Biobank needs to maintain association with one specific NCTN Group and needs to be endorsed in that role by the group leaders. NCTN Biobanks will also support biobanking and storage of biospecimens from NCORP cancer control and prevention trials (NCORP/Division of Cancer Prevention; DCP).
Version: 1





Visit the Official Webpage For More Details on Limited Competition: Biospecimen Banks to support NCI National Clinical Trials Network (NCTN)(U24 Clinical Trial Not Allowed)